SHR-3167 + insulin glargine

SHR-3167 + insulin glargine refers to the clinical evaluation or combination of SHR-3167, an investigational long-acting basal insulin analog, and insulin glargine, a standard-of-care basal insulin. Developed by Jiangsu Hengrui Pharmaceuticals, SHR-3167 is designed for the treatment of type 2 diabetes mellitus. It acts as an agonist of the insulin receptor, mimicking the physiological role of endogenous insulin to regulate glucose metabolism by promoting peripheral glucose uptake and inhibiting hepatic glucose production. Phase I clinical trials have focused on comparing the pharmacokinetics, pharmacodynamics, and safety profile of SHR-3167 against insulin glargine (U100) in both healthy volunteers and patients with type 2 diabetes to establish its potential as a long-acting basal therapy.

Other names

SHR-3167 injection + glargine insulin